We’re Stronger Together
With your help, we can advance education and improve student success in our community.
Research Projects & Grants
For Profit Organization
- A long-term, open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis (JIA), Role: PI, Pfizer Pharmaceuticals, (05/2022 - 05/2023) Status: Completed
- Efficacy, safety and tolerability of tofacitinib for treatment of polyarticular course juvenile idiopathic arthritis (JIA) in children and adolescent subjects, Role: PI, Pfizer Inc., U.S. Pharmaceuticals Group, (10/2018 - 10/2019) Status: Completed
- CMX001 350 A multicenter, open-label study of CMX001 treatment of serious diseases or conditions caused by dsDNA viruses, Role: Investigator, Chimerix, Inc, (06/2012 - 06/2013) Status: Completed
- A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of Obinutuzumab in adolescent patients with active class III or IV Lupus Nephritis, Including an Evaluation of Open-Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to, Role: PI, Hoffmann-La Roche Inc., (12/2025 - 12/2026) Status: Approved
- An open-label, multicenter study to evaluate the pharmacokinetics, safety and tolerability up to 6 years of intravenous secukinumab infusions in pediatric participants with Juvenile Psoriatic Arthritis, Role: PI, Novartis Pharmaceuticals Corporation, (12/2025 - 12/2026) Status: Approved
State
- Song-Brown Healthcare Workforce Training Program Grant-THC SACHS, Role: Faculty, Office of Statewide Health Planning and Development, (01/2020 - 09/2021) Status: Closed